ERT, estrogen replacement therapy Characteristics of patients with GHD as divided by the 15 ng/ml 25(OH)D cutoff. Age and BMI are given as mean ± SD, rhGH dose as median with interquartile range; categorial variables are presented as absolute and relative frequencies Tabelle mod. nach Ameri P et al. 2013

Flow diagram of study selection and exclusion stages Abbildung mod. nach Appelman-Dijkstra NM et al. 2013

Comparison of IGF1 SDS at baseline (groups 1, 2, 3 and 4) with relation to change in phenotypic features after 24 months compared with baseline before GH replacement. Significant differences between groups were demonstrated for body weight (group 1 vs groups 2, 3, and 4, P<0.01), BMI (group 1 vs groups 2 and 4, P<0.003 vs group 3, P<0.05), cholesterol (group 1 vs 3, P<0.015), triglycerides (group 1 vs 3 and group 2 vs 3, P<0.01), and IGF SDS (all comparisons P<0.001) Abbildung mod. nach Feldt-Rasmussen U et al. 2013

Flow diagram of study selection *One publication can cover multiple clinical end-points. GHD, growth hormone deficiency; GH, growth hormone; CVD, cardiovascular disease Abbildung mod. nach van Bunderen CC et al. 2014

Literature identification *Based on the expertise of the authors or suggestions during the peer review process Abbildung mod. nach Gasco V et al. 2013

BMI increase per year during GH substitution pause BMI increase per year during GH substitution pause. We represent the mean and standard deviation of BMI increase per year in males (light blue line and hatching) and females (dark blue line and hatching). Triangles and dots represent males and females respectively. The increase in BMI per year appears to be more pronounced along the first year of GH therapy pause to recover along the time Abbildung mod. nach Bazarra-Castro MÁ et al. 2012